• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>other >Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: Proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008.
【2h】

Spectrum of activity testing for therapeutics against all four dengue virus serotypes in AG129 mouse models: Proof-of-concept studies with the adenosine nucleoside inhibitor NITD-008.

机译：在AG129小鼠模型中针对所有四种登革热病毒血清型的治疗剂的活性测试的频谱：用腺苷核苷抑制剂NITD-008进行的概念验证研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Dengue is a mosquito-borne disease of global public health importance caused by four genetically and serologically related viruses (DENV-1 to DENV-4). Efforts to develop effective vaccines and therapeutics for dengue have been slowed by the paucity of preclinical models that mimic human disease. DENV-2 models in interferon receptor deficient AG129 mice were an important advance but only allowed testing against a single DENV serotype. We have developed complementary AG129 mouse models of severe disseminated dengue infection using strains of the other three DENV serotypes. Here we used the adenosine nucleoside inhibitor NITD-008 to show that these models provide the ability to perform comparative preclinical efficacy testing of candidate antivirals in vivo against the full-spectrum of DENV serotypes. Although NITD-008 was effective in modulating disease caused by all DENV serotypes, the variability in protection among DENV serotypes was greater than expected from differences in activity in in vitro testing studies emphasizing the need to undertake spectrum of activity testing to help in prioritization of candidate compounds for further development.
机译：登革热是一种由蚊子传播的疾病，对全球公共卫生具有重要意义，它由四种遗传和血清学相关病毒（DENV-1至DENV-4）引起。由于缺乏模仿人类疾病的临床前模型，开发登革热有效疫苗和治疗剂的努力已减缓。干扰素受体缺陷型AG129小鼠的DENV-2模型是一项重要进步，但仅允许针对单个DENV血清型进行测试。我们使用其他三种DENV血清型的菌株，开发了严重传播的登革热感染的互补AG129小鼠模型。在这里，我们使用腺苷核苷抑制剂NITD-008来表明，这些模型提供了针对DENV血清型全谱在体内进行候选抗病毒剂的比较临床前功效测试的能力。尽管NITD-008在调节所有DENV血清型引起的疾病方面有效，但是DENV血清型之间的保护变异性大于体外测试研究中活性差异所预期的结果，强调需要进行活性谱以帮助确定候选者的优先级化合物的进一步开发。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号